Generate:Biomedicines, a Flagship Pioneering‑backed biotech that applies machine learning to antibody and protein engineering, filed to go public while advancing an anti‑TSLP antibody into Phase 3 and other programs through earlier clinical stages. The filing cited AI‑driven design speed and partnered validation as core commercial arguments for public investors. The move puts another AI‑native drug developer before public markets following recent successful IPOs, testing investor appetite for companies that combine computational platforms with clinical assets. Generate plans to use proceeds to advance late‑stage programs and expand its programmable biology pipeline.